More About "Tears for Life"

Tears for Life is a medical diagnostic equipment company that is developing a non-invasive tear test kit that will reliably screen women for breast cancer using proteins found in women’s tears. The University of Arkansas for Medical Sciences (UAMS) has a patent pending on the method of using tears to detect cancer as well as the protein patterns discovered. We have an exclusive license from UAMS granting use of the technology.
Tears for Life will guide the tear test kit through various value creating milestones, including protein sequencing and validation, prototype development, clinical trial completion, and FDA clearance. Production of the kit will be outsourced to a company such as Boston BioProducts or Cayman Chemical. The kit will cost $1 to produce and will sell for $100. We will distribute through Cardinal Health or McKesson. The kit will initially be marketed in the U.S. for use in a doctor’s office. We will then introduce a home-based kit, expand internationally, and target R&D towards using tears as a screening medium for other types of cancers, such as ovarian, where it has already shown promising results.
The total annual market size for the tear test kit in the U.S. is $15 billion and $30 billion worldwide. Additionally, the kit will help reduce breast cancer costs by up to $18 billion per year, or about 45%, in the U.S. alone. Current competition for the tear test kit includes annual screening mammograms (49% of women ages 40 and over) and no annual screening (51%). The reasons women do not get screened as frequently as they should include inconvenience, physical discomfort, limitations in accuracy, and high cost. The competitive advantage of the tear test kit is derived from its convenience, lower cost, and elimination of discomfort. These competitive advantages position the tear test kit as an innovative screening tool that will increase screening rates, save lives, and reduce breast cancer treatment costs.